{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:04:09Z","timestamp":1790291049078,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2006,10,12]],"date-time":"2006-10-12T00:00:00Z","timestamp":1160611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent evidence confirms the presence of erythropoietin receptors on a variety of cancer cells. This has raised concerns about the use of erythropoiesis-stimulating agents in the treatment of cancer-related anemia. Having previously identified expression of functional erythropoietin receptors in a non-small cell lung carcinoma cell line, H838, which activated key signaling pathways in response to erythropoietin stimulation, we now demonstrate impaired downregulation of the erythropoietin receptor in these tumor cells. The erythropoietin receptor is not ubiquitinated following erythropoietin stimulation in this cancer cell line, and there is no turnover of the receptor in either unstimulated or stimulated cells. Compounding this blunted response is impaired SOCS3 induction downstream of erythropoietin stimulation and an extremely delayed SOCS1 response. If this finding in non-small cell lung carcinoma is a widespread phenomenon, then impaired erythropoietin receptor downregulation and degradation in tumor cells has clinical implications for those patients receiving erythropoiesis-stimulating agents for cancer-related anemia.<\/jats:p>","DOI":"10.1634\/stemcells.2006-0452","type":"journal-article","created":{"date-parts":[[2006,10,13]],"date-time":"2006-10-13T10:52:11Z","timestamp":1160736731000},"page":"380-384","source":"Crossref","is-referenced-by-count":18,"title":["Impaired Downregulation Following Erythropoietin Receptor Activation in Non-Small Cell Lung Carcinoma"],"prefix":"10.1093","volume":"25","author":[{"given":"Elaine A.","family":"Dunlop","sequence":"first","affiliation":[{"name":"Haematology Research Group, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander P.","family":"Maxwell","sequence":"additional","affiliation":[{"name":"Nephrology Research Group, Queen's University, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence R.J.","family":"Lappin","sequence":"additional","affiliation":[{"name":"Haematology Research Group, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,10,12]]},"reference":[{"key":"2022011305221855100_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbadis.2005.03.003","article-title":"Erythropoietin hypersensitivity in primary familial and congenital polycythemia: Role of tyrosines Y285 and Y344 in erythropoietin receptor cytoplasmic domain","volume":"1740","author":"Arcasoy","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"2022011305221855100_bib2","first-page":"11208","article-title":"Functional erythropoietin receptor of the cells with neural characteristics","volume":"268","author":"Masuda","year":"1993","journal-title":"Comparison with receptor properties of erythroid cells. J Biol Chem"},{"key":"2022011305221855100_bib3","doi-asserted-by":"crossref","first-page":"39754","DOI":"10.1074\/jbc.M004999200","article-title":"Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts","volume":"275","author":"Ogilvie","year":"2000","journal-title":"J Biol Chem"},{"key":"2022011305221855100_bib4","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1073\/pnas.91.9.3974","article-title":"Erythropoietin receptor mRNA expression in human endothelial cells","volume":"91","author":"Anagnostou","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022011305221855100_bib5","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1471-4159.2005.03597.x","article-title":"Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury in vitro","volume":"96","author":"Liu","year":"2006","journal-title":"J Neurochem"},{"key":"2022011305221855100_bib6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1523-1755.2000.00211.x","article-title":"Erythropoietin stimulates proliferation of human renal carcinoma cells","volume":"58","author":"Westenfelder","year":"2000","journal-title":"Kidney Int"},{"key":"2022011305221855100_bib7","first-page":"3561","article-title":"Erythropoietin and erythropoietin receptor expression in human cancer","volume":"61","author":"Acs","year":"2001","journal-title":"Cancer Res"},{"key":"2022011305221855100_bib8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1078-0432.993.11.3","article-title":"Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas","volume":"11","author":"Dagnon","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2022011305221855100_bib9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.onc.1207294","article-title":"Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity","volume":"23","author":"Liu","year":"2004","journal-title":"Oncogene"},{"key":"2022011305221855100_bib10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/pros.20310","article-title":"Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells","volume":"66","author":"Feldman","year":"2006","journal-title":"Prostate"},{"key":"2022011305221855100_bib11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/030089160208800214","article-title":"Erythropoietin and G-CSF receptors in human tumor cells: Expression and aspects regarding functionality","volume":"88","author":"Westphal","year":"2002","journal-title":"Tumori"},{"key":"2022011305221855100_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000092099","article-title":"Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin","volume":"3","author":"Dunlop","year":"2006","journal-title":"Neurodegenerative Dis"},{"key":"2022011305221855100_bib13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1042\/bj20031420","article-title":"Protein tyrosine phosphatase 1B participates in the down-regulation of erythropoietin receptor signalling","volume":"377","author":"Cohen","year":"2004","journal-title":"Biochem J"},{"key":"2022011305221855100_bib14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1146\/annurev.immunol.18.1.143","article-title":"Negative regulators of cytokine signalling pathways","volume":"18","author":"Yasukawa","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"2022011305221855100_bib15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood-2004-03-1216","article-title":"Both proteasomes and lysosomes degrade the activated erythropoietin receptor","volume":"105","author":"Walrafen","year":"2005","journal-title":"Blood"},{"key":"2022011305221855100_bib16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0092-8674(95)90351-8","article-title":"Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals","volume":"80","author":"Klingm\u00fcller","year":"1995","journal-title":"Cell"},{"key":"2022011305221855100_bib17","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1182\/blood-2005-10-4066","article-title":"Anti-Epo receptor antibodies do not predict Epo receptor expression","volume":"107","author":"Elliott","year":"2006","journal-title":"Blood"},{"key":"2022011305221855100_bib18","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/PL00000801","article-title":"The suppressors of cytokine signalling (SOCS)","volume":"58","author":"Kile","year":"2001","journal-title":"Cell Mol Life Sci"},{"key":"2022011305221855100_bib19","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1089\/107999002760274863","article-title":"Differential roles of SOCS family members in EpoR signal transduction","volume":"22","author":"Jegalian","year":"2002","journal-title":"J Interferon Cytokine Res"},{"key":"2022011305221855100_bib20","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1128\/MCB.19.7.4980","article-title":"SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation","volume":"19","author":"Cohney","year":"1999","journal-title":"Mol Cell Biol"},{"key":"2022011305221855100_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0301-472X(98)00003-4","article-title":"A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation","volume":"27","author":"Arcasoy","year":"1999","journal-title":"Exp Hematol"},{"key":"2022011305221855100_bib22","doi-asserted-by":"crossref","first-page":"33909","DOI":"10.1074\/jbc.M508118200","article-title":"Proteasomes mediate prolactin-induced receptor down-regulation and fragment generation in breast cancer cells","volume":"280","author":"Lu","year":"2005","journal-title":"J Biol Chem"},{"key":"2022011305221855100_bib23","doi-asserted-by":"crossref","first-page":"14133","DOI":"10.1073\/pnas.2232790100","article-title":"SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer","volume":"100","author":"He","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022011305221855100_bib24","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bcp.2005.12.017","article-title":"JAK\/STAT signal transduction: Regulators and implication in hematological malignancies","volume":"71","author":"Valentino","year":"2006","journal-title":"Biochem Pharmacol"}],"container-title":["Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Fstemcells.2006-0452","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/stemcells.2006-0452","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/stemcells.2006-0452","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/25\/2\/380\/41961842\/stmcls_25_2_380.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/25\/2\/380\/41961842\/stmcls_25_2_380.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T12:17:30Z","timestamp":1707308250000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stmcls\/article\/25\/2\/380-384\/6402126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,12]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2006,10,12]]},"published-print":{"date-parts":[[2007,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/stemcells.2006-0452","relation":{},"ISSN":["1066-5099","1549-4918"],"issn-type":[{"value":"1066-5099","type":"print"},{"value":"1549-4918","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,2,1]]},"published":{"date-parts":[[2006,10,12]]}}}